Case study
Biological, Cell and Gene, and Cell-based Gene Therapies Development Outsourcing Trends
Dive into the evolving world of outsourcing in biological, cell and gene, and cell-based gene therapies. BTHT’s team linked the global consulting firm with top CSOs and Directors from leading biopharma organizations. Our expert calls provided a rich exploration of current outsourcing practices, emerging trends, and strategic insights. The detailed perspectives offered by these industry leaders greatly enhanced the client’s understanding of the market dynamics and best practices. This in-depth analysis was crucial for making informed strategic decisions and navigating the complexities of advanced therapy development and outsourcing.
- North America
- US
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- UK
- Global
- Biopharma
- CDMO
- Pharma
- Biotech
CHALLENGE
A global consulting firm was tasked with exploring outsourcing trends in the development of biological, cell and gene, and cell-based gene therapies. The objective was to provide a comprehensive analysis of current outsourcing practices and emerging trends to help a client make strategic decisions in this rapidly evolving field.
BTHT APPROACH
Following a detailed briefing with the consulting firm and a thorough review of the project requirements, the BTHT team swiftly identified key industry experts. They reached out to Chief Scientific Officers (CSOs), and Directors of R&D, CMC (Chemistry, Manufacturing, and Controls), and Manufacturing from leading organizations in the biopharma sector. These experts were chosen for their extensive experience and in-depth knowledge. The BTHT team organized and facilitated a series of expert calls, ensuring that each discussion was both enriching and free of technical issues.
OUTCOME
The BTHT team’s strategic approach provided the client with unparalleled insights from top experts in the field. The calls with CSOs and Directors offered a deep dive into outsourcing trends, development strategies, and best practices for biological, cell and gene, and cell-based gene therapies. The client was highly impressed by the quality and relevance of the information shared, which greatly enhanced their understanding of the market and supported well-informed strategic decisions. The expert insights proved invaluable for navigating the complexities and opportunities in the development and outsourcing of advanced therapies.
Let's talk about your project
Reach our CEO Alexis Capelle directly or send us a message — we typically reply within one business day.